度普利尤单抗治疗日本中重度特应性皮炎患者的疗效与安全性:三项临床试验的亚组分析
该研究分析了三项临床试验中日本中重度特应性皮炎患者的数据,评估度普利尤单抗单用或联合外用糖皮质激素的疗效与安全性。结果显示度普利尤单抗显著改善皮损、瘙痒和生活质量,安全性总体可接受,且可快速降低TARC并逐渐降低IgE。
要点
- 度普利尤单抗单用或联合外用糖皮质激素可显著改善日本中重度AD患者的症状与生活质量。
- 安全性特征与总体研究人群相似,但注射部位反应和结膜炎发生率高于安慰剂。
- 度普利尤单抗可快速降低TARC并逐渐降低IgE,抑制2型炎症生物标志物。
核心结论
- 在日本中重度特应性皮炎成人患者中,度普利尤单抗单用或联合外用糖皮质激素可改善症状与体征,安全性可接受,并抑制2型炎症生物标志物。
研究设计与样本
- 对三项临床试验的日本队列进行亚组分析:16周IIb期剂量探索试验(AD-1021)、16周III期安慰剂对照单药试验(SOLO 1)和52周III期安慰剂对照联合外用糖皮质激素试验(CHRONOS)。
- 日本患者人数分别为AD-1021 27例、SOLO 1 106例、CHRONOS 117例。
主要发现
- 日本队列基线疾病严重程度数值上高于总体研究人群。
- 与安慰剂相比,度普利尤单抗显著改善AD体征和症状,包括瘙痒和患者生活质量,与总体研究人群一致。
- 度普利尤单抗在日本队列中的总体安全性特征与总研究人群相似;与安慰剂相比,注射部位反应和结膜炎发生率增加。
- 度普利尤单抗与胸腺和激活调节趋化因子(TARC)快速降低及IgE逐渐降低相关。
临床怎么用
- 对于日本中重度特应性皮炎成人患者,可考虑使用度普利尤单抗单用或联合外用糖皮质激素治疗。
- 治疗中需关注注射部位反应和结膜炎的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13. International phase II and III studies have evaluated the efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis (AD), but the effects of dupilumab in Japanese patients have not been reported. OBJECTIVES: To evaluate the efficacy and safety of dupilumab in Japanese patients with moderate-to-severe AD. METHODS: We analysed the efficacy and safety of dupilumab in the Japanese cohorts of a 16-week, phase IIb dose-finding trial (AD-1021; NCT01859988); a 16-week, phase III, placebo-controlled monotherapy trial (LIBERTY AD SOLO 1; NCT02277743) and a 52-week, phase III, placebo-controlled study of dupilumab with topical corticosteroids (LIBERTY AD CHRONOS; NCT02260986). RESULTS: Twenty-seven, 106 and 117 Japanese patients were enrolled in AD-1021, SOLO 1 and CHRONOS, respectively. Baseline disease severity was numerically higher in the Japanese cohort than in the overall study population. Generally, dupilumab significantly improved signs and symptoms of AD, including pruritus and patient quality of life, compared with placebo in the Japanese cohort, consistent with the overall study population. The combined safety profile of dupilumab in the Japanese cohort was similar to that in the total study populations; dupilumab was associated with an increased incidence of injection-site reactions and conjunctivitis compared with placebo. Dupilumab was associated with rapid reduction in thymus and activation-regulated chemokine and gradual IgE reductions. CONCLUSIONS: Dupilumab alone or with topical corticosteroids improved signs and symptoms of AD, had an acceptable safety profile, and suppressed biomarkers of type 2 inflammation compared with placebo in Japanese adult patients with moderate-to-severe AD. What's already known about this topic? Differences in atopic dermatitis (AD) pathology have been reported between Asian and Western populations, in which distinct helper T-cell activation profiles have been observed. International clinical studies in adults with moderate-to-severe AD have evaluated the efficacy and safety of dupilumab, which blocks interleukin-4 and interleukin-13, key molecules in type 2 inflammation. The effects of dupilumab in Japanese patients specifically have not yet been reported. What does this study add? Dupilumab alone or with topical corticosteroids improved signs and symptoms of AD and had an acceptable safety profile compared with placebo in Japanese patients with moderate-to-severe AD. The effects were comparable with those observed in the overall study population. Reported immunological differences in AD pathology in Asian patients may be secondary to type 2 immune activation.
引用
- Katoh N, Kataoka Y, Saeki H, et al. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol. 2019. PMID: 31564057. doi:10.1111/bjd.18565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。